080907Rompun Xylazine Injection 100mgmL 50 mL and 2 more items

Virginia Commonwealth University (VCU) awarded a contract to Covetrus North America on October 6, 2026, for the supply of pharmaceutical products. The cumulative contract value is $461. The deliverables consist of three pharmaceutical line items to be delivered to VCU Procurement: Rompun Xylazine Injection 100mg/mL (50 mL) at a unit price of $20.40; Ketaset Injection 100mg/mL (10 mL) at a unit price of $19.10; and Ethiqa XR Injection 13mg/mL (3 mL) at a unit price of $422.45. Each item was ordered in a quantity of one unit.

This contract represents a single procurement action for veterinary and/or laboratory pharmaceutical supplies. The low cumulative contract value and unit-specific ordering pattern indicate this award may constitute a one-time purchase or small-scale supply requirement rather than an ongoing requirements contract. All deliverables are designated for VCU Procurement, identifying Virginia Commonwealth University as the location of performance. No period of performance dates beyond the award date of October 6, 2026, are specified in the contract documentation.